Methylation subtypes and large-scale epigenetic alterations in gastric cancer

Science Translational Medicine

Volumn 4, Issue 156, 2012, Pages

  Zouridis, Hermioni ^a,j   Deng, Niantao ^a,b   Ivanova, Tatiana ^a   Zhu, Yansong ^a   Wong, Bernice ^c   Huang, Dan ^d   Wu, Yong Hui ^a,c   Wu, Yingting ^a,e   Tan, Iain Beehuat ^b,c   Liem, Natalia ^f   Gopalakrishnan, Veena ^a   Luo, Qin ^a   Wu, Jeanie ^c   Lee, Minghui ^c   Yong, Wei Peng ^f,g   Goh, Liang Kee ^a   Teh, Bin Tean ^a,c,d   Rozen, Steve ^a,h   Tan, Patrick ^a,c,f,i  

^a DUKE NUS MEDICAL SCHOOL   (Singapore)

^b NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

^c DIVISION OF MEDICAL ONCOLOGY   (Singapore)

^d VAN ANDEL RESEARCH INSTITUTE   (United States)

^e NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

^f NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

^g NATIONAL UNIVERSITY HOSPITAL   (Singapore)

^h DUKE UNIVERSITY MEDICAL CENTER   (United States)

ⁱ GENOME INSTITUTE OF SINGAPORE   (Singapore)

^j LabConnect LLC   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

5 AZA 2' DEOXYCYTIDINE; CISPLATIN; DNA;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER CELL CULTURE; CANCER INHIBITION; CANCER STAGING; CHROMOSOMAL INSTABILITY; CONTROLLED STUDY; CPG ISLAND; DNA METHYLATION; DRUG SENSITIVITY; EMBRYO; EPIGENETICS; EPITHELIUM CELL; GENE CLUSTER; GENE EXPRESSION PROFILING; GENE LOCATION; GENE SILENCING; GENETIC ASSOCIATION; GENETIC CORRELATION; HUMAN; HUMAN CELL; HUMAN TISSUE; MAJOR CLINICAL STUDY; MOUSE; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; PROMOTER REGION; STOMACH CANCER; STOMACH EPITHELIUM; TRANSCRIPTION INITIATION SITE; TUMOR GENE;

ANIMALS; AZACITIDINE; CELL PROLIFERATION; CHROMOSOMAL INSTABILITY; CLUSTER ANALYSIS; CPG ISLANDS; DNA METHYLATION; EPIGENESIS, GENETIC; EPIGENOMICS; GENE EXPRESSION REGULATION, NEOPLASTIC; GENE SILENCING; HUMANS; MICE; NEOPLASM TRANSPLANTATION; PHENOTYPE; STOMACH; STOMACH NEOPLASMS;

EID: 84867820420     PISSN: 19466234     EISSN: 19466242     Source Type: Journal    
DOI: 10.1126/scitranslmed.3004504     Document Type: Article

References (54)

1. H. Brenner, D. Rothenbacher, V. Arndt, Epidemiology of stomach cancer. Methods Mol. Biol. 472, 467-477 (2009).
2. S. S. Wöhrer, M. Raderer, M. Hejna, Palliative chemotherapy for advanced gastric cancer. Ann. Oncol. 15, 1585-1595 (2004).
3. W. K. Leung, M. S. Wu, Y. Kakugawa, J. J. Kim, K. G. Yeoh, K. L. Goh, K. C. Wu, D. C. Wu, J. Sollano, U. Kachintorn, T. Gotoda, J. T. Lin, W. C. You, E. K. Ng, J. J. Sung; Asia Pacific Working Group on Gastric Cancer, Screening for gastric cancer in Asia: Current evidence and practice. Lancet Oncol. 9, 279-287 (2008).
4. H. H. Hartgrink, E. P. Jansen, N. C. van Grieken, C. J. van de Velde, Gastric cancer. Lancet 374, 477-490 (2009).
5. J. G. Strickler, J. Zheng, Q. Shu, L. J. Burgart, S. R. Alberts, D. Shibata, p53 mutations and microsatellite instability in sporadic gastric cancer: When guardians fail. Cancer Res. 54, 4750-4755 (1994).
6. Y. Kimura, T. Noguchi, K. Kawahara, K. Kashima, T. Daa, S. Yokoyama, Genetic alterations in 102 primary gastric cancers by comparative genomic hybridization: Gain of 20q and loss of 18q are associated with tumor progression. Mod. Pathol. 17, 1328-1337 (2004).
7. P. A. Jones, S. B. Baylin, The epigenomics of cancer. Cell 128, 683-692 (2007).
8. A. P. Feinberg, B. Vogelstein, Hypomethylation distinguishes genes of some human cancers from their normal counterparts. Nature 301, 89-92 (1983).
9. M. Toyota, N. Ahuja, H. Suzuki, F. Itoh, M. Ohe-Toyota, K. Imai, S. B. Baylin, J. P. Issa, Aberrant methylation in gastric cancer associated with the CpG island methylator phenotype. Cancer Res. 59, 5438 - 5442 (1999).
10. K. Suzuki, I. Suzuki, A. Leodolter, S. Alonso, S. Horiuchi, K. Yamashita, M. Perucho, Global DNA demethylation in gastrointestinal cancer is age dependent and precedes genomic damage. Cancer Cell 9, 199-207 (2006).
11. S. Y. Park, M. C. Kook, Y. W. Kim, N. Y. Cho, N. Jung, H. J. Kwon, T. Y. Kim, G. H. Kang, CpG island hypermethylator phenotype in gastric carcinoma and its clinicopathological features. Virchows Arch. 457, 415-422 (2010).
12. M. E. Figueroa, S. Lugthart, Y. Li, C. Erpelinck-Verschueren, X. Deng, P. J. Christos, E. Schifano, J. Booth, W. van Putten, L. Skrabanek, F. Campagne, M. Mazumdar, J. M. Greally, P. J. Valk, B. Löwenberg, R. Delwel, A. Melnick, DNA methylation signatures identify biologically distinct subtypes in acute myeloid leukemia. Cancer Cell 17, 13 -27 (2010).
13. H. Noushmehr, D. J. Weisenberger, K. Diefes, H. S. Phillips, K. Pujara, B. P. Berman, F. Pan, C. E. Pelloski, E. P. Sulman, K. P. Bhat, R. G. Verhaak, K. A. Hoadley, D. N. Hayes, C. M. Perou, H. K. Schmidt, L. Ding, R. K. Wilson, D. Van Den Berg, H. Shen, H. Bengtsson, P. Neuvial, L. M. Cope, J. Buckley, J. G. Herman, S. B. Baylin, P. W. Laird, K. Aldape; Cancer Genome Atlas Research Network, Identification of a CpG island methylator phenotype that defines a distinct subgroup of glioma. Cancer Cell 17, 510-522 (2010).
14. R. A. Irizarry, C. Ladd-Acosta, B. Wen, Z. Wu, C. Montano, P. Onyango, H. Cui, K. Gabo, M. Rongione, M. Webster, H. Ji, J. B. Potash, S. Sabunciyan, A. P. Feinberg, The human colon cancer methylome shows similar hypo- and hypermethylation at conserved tissue-specific CpG island shores. Nat. Genet. 41, 178-186 (2009).
15. M. W. Coolen, C. Stirzaker, J. Z. Song, A. L. Statham, Z. Kassir, C. S. Moreno, A. N. Young, V. Varma, T. P. Speed, M. Cowley, P. Lacaze, W. Kaplan, M. D. Robinson, S. J. Clark, Consolidation of the cancer genome into domains of repressive chromatin by long-range epigenetic silencing (LRES) reduces transcriptional plasticity. Nat. Cell Biol. 12, 235-246 (2010).
16. M. Bibikova, J. Le, B. Barnes, S. Saedinia-Melnyk, L. Zhou, R. Shen, K. L. Gunderson, Genome-wide DNA methylation profiling using Infinium assay. Epigenomics 1, 177-200 (2009).
17. Y. Kobayashi, D. M. Absher, Z. G. Gulzar, S. R. Young, J. K. McKenney, D. M. Peehl, J. D. Brooks, R. M. Myers, G. Sherlock, DNA methylation profiling reveals novel biomarkers and important roles for DNA methyltransferases in prostate cancer. Genome Res. 21, 1017-1027 (2011).
18. T. Hinoue, D. J. Weisenberger, C. P. Lange, H. Shen, H. M. Byun, D. Van Den Berg, S. Malik, F. Pan, H. Noushmehr, C. M. van Dijk, R. A. Tollenaar, P. W. Laird, Genome-scale analysis of aberrant DNA methylation in colorectal cancer. Genome Res. 22, 271-282 (2012).
19. F. Eckhardt, J. Lewin, R. Cortese, V. K. Rakyan, J. Attwood, M. Burger, J. Burton, T. V. Cox, R. Davies, T. A. Down, C. Haefliger, R. Horton, K. Howe, D. K. Jackson, J. Kunde, C. Koenig, J. Liddle, D. Niblett, T. Otto, R. Pettett, S. Seemann, C. Thompson, T. West, J. Rogers, A. Olek, K. Berlin, S. Beck, DNA methylation profiling of human chromosomes 6, 20 and 22. Nat. Genet. 38, 1378 -1385 (2006).
20. C. H. Ooi, T. Ivanova, J. Wu, M. Lee, I. B. Tan, J. Tao, L.Ward, J. H. Koo, V. Gopalakrishnan, Y. Zhu, L. L. Cheng, J. Lee, S. Y. Rha, H. C. Chung, K. Ganesan, J. So, K. C. Soo, D. Lim, W. H. Chan, W. K. Wong, D. Bowtell, K. G. Yeoh, H. Grabsch, A. Boussioutas, P. Tan, Oncogenic pathway combinations predict clinical prognosis in gastric cancer. PLoS Genet. 5, e1000676 (2009).
21. D. Deng, W. El-Rifai, J. Ji, B. Zhu, P. Trampont, J. Li, M. F. Smith, S. M. Powel, Hypermethylation of metallothionein-3 CpG island in gastric carcinoma. Carcinogenesis 24, 25-29 (2003).
22. Study Group of Millennium Genome Project for Cancer; H. Sakamoto, K. Yoshimura, N. Saeki, H. Katai, T. Shimoda, Y. Matsuno, D. Saito, H. Sugimura, F. Tanioka, S. Kato, N. Matsukura, N. Matsuda, T. Nakamura, I. Hyodo, T. Nishina, W. Yasui, H. Hirose, M. Hayashi, E. Toshiro, S. Ohnami, A. Sekine, Y. Sato, H. Totsuka, M. Ando, R. Takemura, Y. Takahashi, M. Ohdaira, K. Aoki, I. Honmyo, S. Chiku, K. Aoyagi, H. Sasaki, S. Ohnami, K. Yanagihara, K. A. Yoon, M. C. Kook, Y. S. Lee, S. R. Park, C. G. Kim, I. J. Choi, T. Yoshida, Y. Nakamura, S. Hirohashi, Genetic variation in PSCA is associated with susceptibility to diffuse-type gastric cancer. Nat. Genet. 40, 730-740 (2008).
23. A. Subramanian, P. Tamayo, V. K. Mootha, S. Mukherjee, B. L. Ebert, M. A. Gillette, A. Paulovich, S. L. Pomeroy, T. R. Golub, E. S. Lander, J. P. Mesirov, Gene set enrichment analysis: A knowledge-based approach for interpreting genome-wide expression profiles. Proc. Natl. Acad. Sci. U.S.A. 102, 15545-15550 (2005).
24. V. K. Mootha, C. M. Lindgren, K. F. Eriksson, A. Subramanian, S. Sihag, J. Lehar, P. Puigserver, E. Carlsson, M. Ridderstråle, E. Laurila, N. Houstis, M. J. Daly, N. Patterson, J. P. Mesirov, T. R. Golub, P. Tamayo, B. Spiegelman, E. S. Lander, J. N. Hirschhorn, D. Altshuler, L. C. Groop, PGC-1 a-responsive genes involved in oxidative phosphorylation are coordinately downregulated in human diabetes. Nat. Genet. 34, 267-273 (2003).
25. M. Vecchi, P. Nuciforo, S. Romagnoli, S. Confalonieri, C. Pellegrini, G. Serio, M. Quarto, M. Capra, G. C. Roviaro, E. Contessini Avesani, C. Corsi, G. Coggi, P. P. Di Fiore, S. Bosari, Gene expression analysis of early and advanced gastric cancers. Oncogene 26, 4284-4294 (2007).
26. Y. Wu, M. S. Siadaty, M. E. Berens, G. M. Hampton, D. Theodorescu, Overlapping gene expression profiles of cell migration and tumor invasion in human bladder cancer identify metallothionein 1E and nicotinamide N-methyltransferase as novel regulators of cell migration. Oncogene 27, 6679-6689 (2008).
27. S. Senese, K. Zaragoza, S. Minardi, I. Muradore, S. Ronzoni, A. Passafaro, L. Bernard, G. F.Draetta, M. Alcalay, C. Seiser, S. Chiocca, Role for histone deacetylase 1 in human tumor cell proliferation. Mol. Cell. Biol. 27, 4784-4795 (2007).
28. M. Nuytten, L. Beke, A. Van Eynde, H. Ceulemans, M. Beullens, P. Van Hummelen, F. Fuks, M. Bollen, The transcriptional repressor NIPP1 is an essential player in EZH2-mediated gene silencing. Oncogene 27, 1449-1460 (2008).
29. B. Carvalho, M. Pinto, L. Cirnes, C. Oliveira, J. C. Machado, G. Suriano, R. Hamelin, F. Carneiro, R. Seruca, Concurrent hypermethylation of gene promoters is associated with a MSI-H phenotype and diploidy in gastric carcinomas. Eur. J. Cancer 39, 1222-1227 (2003). Downloaded from stm.sciencemag.org on October 17, 2012
30. C. An, I. S. Choi, J. C. Yao, S. Worah, K. Xie, P. F. Mansfield, J. A. Ajani, A. Rashid, S. R. Hamilton, T. T. Wu, Prognostic significance of CpG island methylator phenotype and microsatellite instability in gastric carcinoma. Clin. Cancer Res. 11, 656-663 (2005).
31. N. Oue, Y. Oshimo, H. Nakayama, R. Ito, K. Yoshida, K. Matsusaki, W. Yasui, DNA methylation of multiple genes in gastric carcinoma: Association with histological type and CpG island methylator phenotype. Cancer Sci. 94, 901-905 (2003).
32. E. Yamamoto, H. Suzuki, H. Takamaru, H. Yamamoto, M. Toyota, Y. Shinomura, Role of DNA methylation in the development of diffuse-type gastric cancer. Digestion 83, 241-249 (2011).
33. J. C. Newman, A. M. Weiner, L2L: A simple tool for discovering the hidden significance in microarray expression data. Genome Biol. 6, R81 (2005).
34. I. Ben-Porath, M. W. Thomson, V. J. Carey, R. Ge, G. W. Bell, A. Regev, R. A. Weinberg, An embryonic stem cell-like gene expression signature in poorly differentiated aggressive human tumors. Nat. Genet. 40, 499-507 (2008).
35. E. Kaminskas, A. T. Farrell, Y. C. Wang, R. Sridhara, R. Pazdur, FDA drug approval summary: Azacitidine (5-azacytidine, Vidaza) for injectable suspension. Oncologist 10, 176-182 (2005).
36. K. Yamashita, S. Upadhyay, M. Osada, M. O. Hoque, Y. Xiao, M. Mori, F. Sato, S. J. Meltzer, D. Sidransky, Pharmacologic unmasking of epigenetically silenced tumor suppressor genes in esophageal squamous cell carcinoma. Cancer Cell 2, 485-495 (2002).
37. M. Shiraishi, A. Sekiguchi, A. J. Oates, M. J. Terry, Y. Miyamoto, HOX gene clusters are hotspots of de novo methylation in CpG islands of human lung adenocarcinomas. Oncogene 21, 3659-3662 (2002).
38. N. Deng, L. K. Goh, H. Wang, K. Das, J. Tao, I. B. Tan, S. Zhang, M. Lee, J. Wu, K. H. Lim, Z. Lei, G. Goh, Q. Y. Lim, A. L. Tan, D. Y. Sin Poh, S. Riahi, S. Bell, M. M. Shi, R. Linnartz, F. Zhu, K. G. Yeoh, H. C. Toh, W. P. Yong, H. C. Cheong, S. Y. Rha, A. Boussioutas, H. Grabsch, S. Rozen, P. Tan, A comprehensive survey of genomic alterations in gastric cancer reveals systematic patterns of molecular exclusivity and co-occurrence among distinct therapeutic targets. Gut 61, 673-684 (2012).
39. B. P. Berman, D. J.Weisenberger, J. F. Aman, T. Hinoue, Z. Ramjan, Y. Liu, H. Noushmehr, C. P. Lange, C. M. van Dijk, R. A. Tollenaar, D. Van Den Berg, P. W. Laird, Regions of focal DNA hypermethylation and long-range hypomethylation in colorectal cancer coincide with nuclear lamina-associated domains. Nat. Genet. 44, 40-46 (2011).
40. X. Zhang, M. Wu, H. Xiao, M. T. Lee, L. Levin, Y. K. Leung, S. M. Ho, Methylation of a single intronic CpG mediates expression silencing of the PMP24 gene in prostate cancer. Prostate 70, 765-776 (2010).
41. B. Li, M. Carey, J. L. Workman, The role of chromatin during transcription. Cell 128, 707-719 (2007).
42. M. P. Ball, J. B. Li, Y. Gao, J. H. Lee, E. M. LeProust, I. H. Park, B. Xie, G. Q. Daley, G. M. Church, Targeted and genome-scale strategies reveal gene-body methylation signatures in human cells. Nat. Biotechnol. 27, 361-368 (2009).
43. T. A. Rauch, X. Wu, X. Zhong, A. D. Riggs, G. P. Pfeifer, A human B cell methylome at 100 -base pair resolution. Proc. Natl. Acad. Sci. U.S.A. 106, 671-678 (2009).
44. S. Enomoto, T. Maekita, T. Tsukamoto, T. Nakajima, K. Nakazawa, M. Tatematsu, M. Ichinose, T. Ushijima, Lack of association between CpG island methylator phenotype in human gastric cancers and methylation in their background non-cancerous gastric mucosae. Cancer Sci . 98, 1853-1861 (2007).
45. H. Y. Chen, B. H. Zhu, C. H. Zhang, D. J. Yang, J. J. Peng, J. H. Chen, F. K. Liu, Y. L. He, High CpG island methylator phenotype is associated with lymph node metastasis and prognosis in gastric cancer. Cancer Sci. 103, 73-79 (2012).
46. Y. Schlesinger, R. Straussman, I. Keshet, S. Farkash, M. Hecht, J. Zimmerman, E. Eden, Z. Yakhini, E. Ben-Shushan, B. E. Reubinoff, Y. Bergman, I. Simon, H. Cedar, Polycomb-mediated methylation on Lys27 of histone H3 pre-marks genes for de novo methylation in cancer. Nat. Genet. 39, 232-236 (2007).
47. B. H. Min, J. M. Bae, E. J. Lee, H. S. Yu, Y. H. Kim, D. K. Chang, H. C. Kim, C. K. Park, S. H. Lee, K. M. Kim, G. H. Kang, The CpG island methylator phenotype may confer a survival benefit in patients with stage II or III colorectal carcinomas receiving fluoropyrimidine-based adjuvant chemotherapy. BMC Cancer 11, 344 (2011).
48. M. Tasaki, K. Shimada, H. Kimura, K. Tsujikawa, N. Konishi, ALKBH3, a human AlkB homologue, contributes to cell survival in human non-small-cell lung cancer. Br. J. Cancer 104, 700-706 (2011).
49. B. I. Ferreira, J. F. García, J. Suela, M. Mollejo, F. I. Camacho, A. Carro, S. Montes, M. A. Piris, J. C. Cigudosa, Comparative genome profiling across subtypes of low-grade B-cell lymphoma identifies type-specific and common aberrations that target genes with a role in B-cell neoplasia. Haematologica 93, 670-679 (2008).
50. S. Kalari, G. P. Pfeifer, Identification of driver and passenger DNA methylation in cancer by epigenomic analysis. Adv. Genet. 70, 277-308 (2010).
51. T. Ushijima, Epigenetic field for cancerization. J. Biochem. Mol. Biol. 40, 142-150 (2007).
52. A. B. Olshen, E. S. Venkatraman, R. Lucito, M. Wigler, Circular binary segmentation for the analysis of array-based DNA copy number data. Biostatistics 5, 557-572 (2004).
53. Y. Benjamini, Y. Hochberg, Controlling the false discovery rate: A practical and powerful approach to multiple testing. J. R. Statist. Soc. B 57, 289-300 (1995).
54. Q. L. Li, K. Ito, C. Sakakura, H. Fukamachi, K. Inoue, X. Z. Chi, K. Y. Lee, S. Nomura, C. W. Lee, S. B. Han, H. M. Kim, W. J. Kim, H. Yamamoto, N. Yamashita, T. Yano, T. Ikeda, S. Itohara, J. Inazawa, T. Abe, A. Hagiwara, H. Yamagishi, A. Ooe, A. Kaneda, T. Sugimura, T. Ushijima, S. C. Bae, Y. Ito, Causal relationship between the loss of RUNX3 expression and gastric cancer. Cell 109, 113-124 (2002).